Current Issue December 2011, Vol. 4, No. 2

Issue Highlights

  • PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay
    December 2011(Vol. 4 | No. 2 | Pages 54-56)

    J. Tate Thigpen

  • CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
    December 2011(Vol. 4 | No. 2 | Pages 57-61)

    John Farley, Michael J. Birrer

  • PRO: Patients With Endometrial Carcinoma Involving Extrauterine Disease Should, After Any Indicated Surgery, Receive Chemotherapy
    December 2011(Vol. 4 | No. 2 | Pages 62-65)

    J. Tate Thigpen

  • Platelet-Derived Growth Factor Gene Polymorphisms in Patients with Ovarian Cancer
    21 May 2012

    Christine Vestergaard Madsen, Karina Dahl Steffensen, Marianne Waldstrøm, Rikke Fredslund Andersen, Charlotte Hasselholt Søgaard, Ivan Brandslund, Anders Jakobsen

  • Unusual Collision Tumor of Ovary: Endometrioid Adenocarcinoma and Teratoma
    02 February 2012

    Eliyaz Ahmed, Shatrughan P. Sah, Anilkumar Adikesavalu, Krishnaswamy Madhavan, Khalil Razvi

  • Intraperitoneal Catheter Placement: The “Hammock” Technique
    24 October 2011

    Christina L. Kushnir, Aimee C. Fleury, David F. Silver, Nick M. Spirtos

  • View More Articles in Press...

On the Cover



Editor-in-Chief:
J. Tate Thigpen, MD

Companion Journals

Attention Qualified Recipients

If you are a qualified recipient of the US print edition of Clinical Ovarian Cancer, click here to access the online edition.

Access this journal onSciVerse ScienceDirect
Print or Share This Page

About Clinical Ovarian Cancer

Clinical Ovarian Cancer is a peer-reviewed, semi-annual journal that publishes original articles describing various aspects of clinical and translational research in ovarian cancer.

Clinical Ovarian Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of ovarian and other gynecologic cancers. The main emphasis is on recent scientifi c developments in all areas related to gynecologic malignancies.

Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

Journal Access

Full-text articles are available from 2008 to the present. Access to abstracts is complimentary. Access to full text is limited to personal subscribers.

Activate Online Access

Publishing Information

Clinical Ovarian Cancer is published by Elsevier.